Copyright © 2019. Inderes Oy. All rights reserved.
Herantis Pharma
2183 investors follow this company
The company is not covered. See all listed companies from here.
BUY 7.30 LOWEST 7.40 VOLUME 435
SELL 7.40 HIGHEST 7.72 VALUE 0,003 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Upcoming events

27
Aug
Osavuosikatsaukset

Latest insider trading

Net impact profile

Type: stock_exchange_release
18.6.
2020

Herantis Pharma Plc
Company release 18 June 2020 at 10:00 AM Eastern European Summer Time

Herantis Pharma Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Pekka Simula

Position: Chief Executive Officer

Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Notification type: INITIAL NOTIFICATION

Reference number: 743700W4CQVYAT3WKK38_20200617140726_5

____________________________________________

Transaction date: 2020-06-18

Type: stock_exchange_release
18.6.
2020

Herantis Pharma Plc
Company release 18 June 2020 at 10:00 AM Eastern European Summer Time

Herantis Pharma Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Huttunen, Henri

Position: Other senior manager

Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Notification type: INITIAL NOTIFICATION

Reference number: 743700W4CQVYAT3WKK38_20200617141026_6

____________________________________________

Transaction date: 2020-06-18

Type: stock_exchange_release
18.6.
2020

Herantis Pharma Plc
Company release, 18 June 2020 at 9:30 AM Eastern European Summer Time

An aggregate number of 39,600 new shares of Herantis Pharma Plc ("Herantis") have been subscribed for with option rights under the option programs 2010, 2014 and 2016 I. The new shares have been registered with the trade register maintained by the Finnish Patent and Registration Office today. The new shares will confer shareholder rights in Herantis after they have been issued in the book-entry system, on or about 19 June 2020.

Type: stock_exchange_release
27.5.
2020

Herantis Pharma Plc
Company release, 27 May 2020 at 5:00 p.m. Eastern European Summer Time

THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Type: stock_exchange_release
27.5.
2020

Herantis Pharma Plc
Company release, inside information, 27 May 2020 at 9:00 a.m. Eastern European Summer Time

THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Type: stock_exchange_release
26.5.
2020

Herantis Pharma Plc
Company release, inside information, 26 May 2020 at 6:30 p.m. Eastern European Summer Time

THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Type: stock_exchange_release
11.5.
2020

Herantis Pharma Plc
Company release, insider information 11 May 2020 at 9:00 AM Eastern European Time

Herantis Pharma Plc ("Herantis" or "Company") announced today that it has appointed Dr. Craig Cook as its new CEO effective 1[st] of July 2020. Pekka Simula, the current CEO, will continue as CEO of Herantis until that date, followed by a three-month handover period during which Mr. Simula will support Dr. Cook in his role through the transition.

Type: stock_exchange_release
4.5.
2020

Herantis Pharma Plc
Press release 4 May 2020 at 9:00 am Eastern European Time

Herantis Pharma Plc ("Herantis") has published its newsletter for March-April 2020. The newsletter is also attached to this press release.

Herantis' newsletter is published every other month on the company's web site (https://herantis.com/news-events/#newsletter). It is also available by email subscription (https://herantis.com/subscribe/).

Further information:

Type: stock_exchange_release
27.4.
2020

Herantis Pharma Plc
Company release 27 April 2020 at 9:00 AM Eastern European Time

Herantis Pharma Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Inveni Life Sciences Fund I Ky

Position: Closely associated person

(X) Legal person

(1): Person Discharging Managerial Responsibilities In Issuer

Name: Prihti, Aki

Position: Member of the Board

Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Notification type: INITIAL NOTIFICATION

Type: stock_exchange_release
27.4.
2020

Herantis Pharma Plc
Company release 27 April 2020 at 9:00 AM Eastern European Time

Herantis Pharma Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Inveni Pre-Exit Financing Vehicle Ky

Position: Closely associated person

(X) Legal person

(1): Person Discharging Managerial Responsibilities In Issuer

Name: Prihti, Aki

Position: Member of the Board

Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Herantis Pharma

English translation unavailable for Herantis Pharma.
Herantis Pharma